Third, CD22‐directed INO was applied in patient with ALL, a heterogeneous neoplasm of lymphoid progenitors, which consists of 85% B‐cell lineage and 15% T‐cell lineage. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.